ReviewVascular health and risk management2026
Diabetes, Obesity, and the Metabolic Drivers of Peripheral Artery Disease: Lessons from Recent Forecasts.
Review in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral artery disease (PAD) is rapidly emerging as a global health priority, with projections indicating a dramatic rise in prevalence, mortality, and disability by 2050. Recent forecasts project an approximately 220% increase in PAD prevalence, with more than 360 million individuals affected globally by mid-century, largely driven by metabolic diseases-particularly diabetes and obesity. A recent population-based study forecasting the global burden of PAD provides compelling evidence that metabolic disease is the dominant driver of this alarming trend. This commentary highlights the critical interplay between metabolic risk factors and PAD progression, underscores the disproportionate burden expected in low- and middle-income countries, and calls for urgent, integrated strategies targeting metabolic health. Without decisive action to reduce diabetes, obesity, and related metabolic disorders, the looming global PAD crisis will further strain healthcare systems and deepen health inequities worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.